<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39202221</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>16</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Role of Small-Bowel Capsule Endoscopy in the Diagnostic Algorithm of Complicated Perianal Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1733</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics14161733</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Complicated perianal disease (cPD) may be the sole presentation of Crohn's disease (CD). The role of small-bowel capsule endoscopy (SBCE) in the diagnostic algorithm of cPD is unclear. We aimed to evaluate the role of SBCE as a diagnostic tool, in patients with cPD, after a negative standard workup for CD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multicenter, retrospective, cross-sectional study, in patients with cPD, and negative standard workup for CD (ileocolonoscopy and cross-sectional imaging), who underwent SBCE for suspected CD. Demographics, biomarkers, and the Lewis Score (LS) were recorded and analyzed. An LS ≥ 135 was considered a positive SBCE for diagnosing CD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety-one patients were included: 65 (71.4%) males; median age: 37 (29-51) years; cPD duration: 25.1 (12.5-66.1) months. Positive SBCE: 24/91 (26.4%) patients. Fecal calprotectin (FC) positively correlated with LS (<i>r</i> = 0.81; <i>p</i> &lt; 0.001). FC levels of 100 µg/g and 50 µg/g had a sensitivity of only 40% and 55% to rule out small-bowel CD, with a negative predictive value (NPV) of only 76% and 80%, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SBCE contributed to CD diagnosis in a quarter of patients with cPD after a negative standard workup. FC levels correlated with the degree of inflammation defined by the LS. However, the NPV of FC was low, suggesting that SBCE should be considered for patients with cPD even after a negative standard workup.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avni-Biron</LastName><ForeName>Irit</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Rabin Medical Center, Petah Tikva 4941492, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Ervin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9314-9239</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Skåne University Hospital, Lund University, 21428 Malmö, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, 20502 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollech</LastName><ForeName>Jacob E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Rabin Medical Center, Petah Tikva 4941492, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemeth</LastName><ForeName>Artur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Skåne University Hospital, Lund University, 21428 Malmö, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, 20502 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansson</LastName><ForeName>Gabriele Wurm</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Skåne University Hospital, Lund University, 21428 Malmö, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Lund University, 20502 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweinstein</LastName><ForeName>Hagai</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1821-1549</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Rabin Medical Center, Petah Tikva 4941492, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margalit</LastName><ForeName>Reuma Yehuda</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5266202, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopylov</LastName><ForeName>Uri</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5266202, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dotan</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Rabin Medical Center, Petah Tikva 4941492, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanai</LastName><ForeName>Henit</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5483-5271</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Rabin Medical Center, Petah Tikva 4941492, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">algorithm</Keyword><Keyword MajorTopicYN="N">capsule endoscopy</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">fecal calprotectin</Keyword><Keyword MajorTopicYN="N">perianal Crohn’s disease</Keyword></KeywordList><CoiStatement>I.A.-B. reports honoraria for lectures from AbbVie, Janssen, Pfizer, and Takeda, and is a clinical research specialist at Medtronic. J.E.O. reports institutional research grants from Pfizer; honoraria for lectures from AbbVie, Janssen, Pfizer, and Takeda and Bristol Myers Squibb. E.T. received research support from Jinshan, AnX Robotica, and Norgine; as well as consultancy/lecture fee from Jinshan, Medtronic, and Norgine. G.W. reports a lecture fee from Medtronic. U.K. reports speaker and advisory fees from AbbVie Janssen BMS, Pfizer, Medtronic, and Takeda, as well as research support from Jannsen Medtronic Takeda. I.D. received advisory/consultation and speaking support from Abbott, AbbVie, Athos, Arena, Altman, Cambridge Healthcare, Celltrion, Celgene/BMS, Eli-Lilly, Ferring, Falk Pharma, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Integra Holdings, Janssen, Neopharm, Pfizer, Rafa laboratories, Roche/Genentech, Sangamo, Sublimity, Sandoz, Takeda, and Wildbio. Grants: Altman Research, BMS. H.Y. reports institutional research grants from Pfizer and the ISF; consulting fees from AbbVie, Janssen, Pfizer, Takeda, and Bristol Myers Squibb; honoraria for lectures from AbbVie, Janssen, Pfizer, and Takeda; and participation in a Data Safety Monitoring Board or Advisory Board from AbbVie, Pfizer, Takeda, and Bristol Myers Squibb. The remaining authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39202221</ArticleId><ArticleId IdType="pmc">PMC11353184</ArticleId><ArticleId IdType="doi">10.3390/diagnostics14161733</ArticleId><ArticleId IdType="pii">diagnostics14161733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Panés J., Rimola J. Perianal fistulizing Crohn’s disease: Pathogenesis, diagnosis and therapy. Nat. Rev. Gastroenterol. Hepatol. 2017;14:652–664. doi: 10.1038/nrgastro.2017.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.104</ArticleId><ArticleId IdType="pubmed">28790453</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai L., McCurdy J.D., Ma C., Jairath V., Singh S. Epidemiology and Natural History of Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. Inflamm. Bowel Dis. 2021;28:1477–1484. doi: 10.1093/ibd/izab287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab287</ArticleId><ArticleId IdType="pmc">PMC9527611</ArticleId><ArticleId IdType="pubmed">34792604</ArticleId></ArticleIdList></Reference><Reference><Citation>Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., et al. Infliximab for the Treatment of Fistulas in Patients with Crohn’s Disease. N. Engl. J. Med. 1999;340:1398–1405. doi: 10.1056/NEJM199905063401804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199905063401804</ArticleId><ArticleId IdType="pubmed">10228190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., et al. Infliximab Maintenance Therapy for Fistulizing Crohn’s Disease. N. Engl. J. Med. 2004;350:876–885. doi: 10.1056/NEJMoa030815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030815</ArticleId><ArticleId IdType="pubmed">14985485</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarur A.J., Kanagala V., Stein D.J., Czul F., Quintero M.A., Agrawal D., Patel A., Best K., Fox C., Idstein K., et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment. Pharmacol. Ther. 2017;45:933–940. doi: 10.1111/apt.13970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13970</ArticleId><ArticleId IdType="pubmed">28211593</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewint P., Hansen B.E., Verhey E., Oldenburg B., Hommes D.W., Pierik M., Ponsioen C.I.J., van Dullemen H.M., Russel M., van Bodegraven A.A., et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: A randomised, double-blind, placebo controlled trial (ADAFI) Gut. 2013;63:292–299. doi: 10.1136/gutjnl-2013-304488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2013-304488</ArticleId><ArticleId IdType="pubmed">23525574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez N., Ramamoorthy S., Sandborn W.J. Recent advances in the management of perianal fistulizing Crohn’s disease: Lessons for the clinic. Expert Rev. Gastroenterol. Hepatol. 2019;13:563–577. doi: 10.1080/17474124.2019.1608818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474124.2019.1608818</ArticleId><ArticleId IdType="pmc">PMC6545251</ArticleId><ArticleId IdType="pubmed">31023087</ArticleId></ArticleIdList></Reference><Reference><Citation>Panés J., García-Olmo D., Van Assche G., Colombel J.F., Reinisch W., Baumgart D.C., Dignass A., Nachury M., Ferrante M., Kazemi-Shirazi L., et al. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease. Gastroenterology. 2018;154:1334–1342.e4. doi: 10.1053/j.gastro.2017.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.12.020</ArticleId><ArticleId IdType="pubmed">29277560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassin N.A., Askari A., Warusavitarne J., Faiz O.D., Athanasiou T., Phillips R.K.S., Hart A.L. Systematic review: The combined surgical and medical treatment of fistulising perianal Crohn’s disease. Aliment. Pharmacol. Ther. 2014;40:741–749. doi: 10.1111/apt.12906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12906</ArticleId><ArticleId IdType="pubmed">25115149</ArticleId></ArticleIdList></Reference><Reference><Citation>Meima-van Praag E.M., Buskens C.J., Hompes R., Bemelman W.A. Surgical management of Crohn’s disease: A state of the art review. Int. J. Color. Dis. 2021;36:1133–1145. doi: 10.1007/s00384-021-03857-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-021-03857-2</ArticleId><ArticleId IdType="pmc">PMC8119249</ArticleId><ArticleId IdType="pubmed">33528750</ArticleId></ArticleIdList></Reference><Reference><Citation>Maaser C., Sturm A., Vavricka S.R., Kucharzik T., Fiorino G., Annese V., Calabrese E., Baumgart D.C., Bettenworth D., Borralho Nunes P., et al. ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohn’s Colitis. 2018;13:144–164. doi: 10.1093/ecco-jcc/jjy113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjy113</ArticleId><ArticleId IdType="pubmed">30137275</ArticleId></ArticleIdList></Reference><Reference><Citation>Flamant M., Trang C., Maillard O., Sacher-Huvelin S., Le Rhun M., Galmiche J.-P., Bourreille A. The prevalence and outcome of jejunal lesions visualized by small bowel capsule endoscopy in Crohn’s disease. Inflamm. Bowel Dis. 2013;19:1390–1396. doi: 10.1097/MIB.0b013e31828133c1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0b013e31828133c1</ArticleId><ArticleId IdType="pubmed">23552764</ArticleId></ArticleIdList></Reference><Reference><Citation>Greener T., Klang E., Yablecovitch D., Lahat A., Neuman S., Levhar N., Avidan B., Yanai H., Dotan I., Chowers Y., et al. The impact of magnetic resonance enterography and capsule endoscopy on the re-classification of disease in patients with known Crohn’s Disease: A prospective Israeli IBD research nucleus (IIRN) study. J. Crohn’s Colitis. 2016;10:525–531. doi: 10.1093/ecco-jcc/jjw006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjw006</ArticleId><ArticleId IdType="pmc">PMC4957453</ArticleId><ArticleId IdType="pubmed">26748404</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai F.W.D., Ellul P., Elosua A., Fernandez-Urien I., Tontini G.E., Elli L., Eliakim R., Kopylov U., Koo S., Parker C., et al. Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn’s disease: A European multicentre observational cohort study. United Eur. Gastroenterol. J. 2021;9:248–255. doi: 10.1177/2050640620948664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640620948664</ArticleId><ArticleId IdType="pmc">PMC8259365</ArticleId><ArticleId IdType="pubmed">32741315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zittan E., Kelly O.B., Gralnek I.M., Silverberg M.S., Steinhart A.H. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn’s disease activity. JGH Open. 2018;2:201–206. doi: 10.1002/jgh3.12068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12068</ArticleId><ArticleId IdType="pmc">PMC6207015</ArticleId><ArticleId IdType="pubmed">30483590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gecse K.B., Brandse J.F., van Wilpe S., Löwenberg M., Ponsioen C., Brink G.v.D., D’haens G. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand. J. Gastroenterol. 2015;50:841–847. doi: 10.3109/00365521.2015.1008035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2015.1008035</ArticleId><ArticleId IdType="pubmed">25636819</ArticleId></ArticleIdList></Reference><Reference><Citation>Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 2008;103:162–169. doi: 10.1111/j.1572-0241.2007.01556.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01556.x</ArticleId><ArticleId IdType="pubmed">17916108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopylov U., Nemeth A., Koulaouzidis A., Makins R., Wild G., Afif W., Bitton A., Johansson G.W., Bessissow T., Eliakim R., et al. Small bowel capsule endoscopy in the management of established Crohn’s disease: Clinical impact, safety, and correlation with inflammatory biomarkers. Inflamm. Bowel Dis. 2015;21:93–100. doi: 10.1097/MIB.0000000000000255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0000000000000255</ArticleId><ArticleId IdType="pubmed">25517597</ArticleId></ArticleIdList></Reference><Reference><Citation>Spada C., McNamara D., Despott E.J., Adler S., Cash B.D., Fernández-Urién I., Ivekovic H., Keuchel M., McAlindon M., Saurin J.-C., et al. Performance measures for small-bowel endoscopy: A European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. United Eur. Gastroenterol. J. 2019;7:614–641. doi: 10.1177/2050640619850365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640619850365</ArticleId><ArticleId IdType="pmc">PMC6545716</ArticleId><ArticleId IdType="pubmed">31210941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn W.J., Fazio V.W., Feagan B.G., Hanauer S.B., American Gastroenterological Association Clinical Practice Committee AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–1530. doi: 10.1016/j.gastro.2003.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gastro.2003.08.025</ArticleId><ArticleId IdType="pubmed">14598268</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralnek I.M., Defranchis R., Seidman E., Leighton J.A., Legnani P., Lewis B.S. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment. Pharmacol. Ther. 2007;27:146–154. doi: 10.1111/j.1365-2036.2007.03556.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03556.x</ArticleId><ArticleId IdType="pubmed">17956598</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler S.N., Yoav M., Eitan S., Yehuda C., Eliakim R. Does capsule endoscopy have an added value in patients with perianal disease and a negative work up for Crohn’s disease? World J. Gastrointest. Endosc. 2012;4:185–188. doi: 10.4253/wjge.v4.i5.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.4253/wjge.v4.i5.185</ArticleId><ArticleId IdType="pmc">PMC3355241</ArticleId><ArticleId IdType="pubmed">22624070</ArticleId></ArticleIdList></Reference><Reference><Citation>McCurdy J.D., Weng R., Parlow S., Dawkins Y.M., Brar G., Oliveira L., Saloojee N., Murthy S., Kenshil S., Macdonald B., et al. Video Capsule Endoscopy can Identify Occult Luminal Crohn’s Disease in Patients with Isolated Perianal Fistulas. J. Crohn’s Colitis. 2023;17:1624–1630. doi: 10.1093/ecco-jcc/jjad078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjad078</ArticleId><ArticleId IdType="pubmed">37101357</ArticleId></ArticleIdList></Reference><Reference><Citation>Prichard D.O., Hamilton Z., Savage T., Smyth M., Penner C., Lakhani A., Carroll M.W., Al Sarkhy A., Lemberg D.A., Enns R., et al. Capsule Endoscopy Complements Magnetic Resonance Enterography and Endoscopy in Evaluating Small Bowel Crohn’s Disease. J. Can. Assoc. Gastroenterol. 2019;3:279–287. doi: 10.1093/jcag/gwz028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwz028</ArticleId><ArticleId IdType="pmc">PMC7678730</ArticleId><ArticleId IdType="pubmed">33241181</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M.D., Nathan T., Rafaelsen S.R., Kjeldsen J. Diagnostic Accuracy of Capsule Endoscopy for Small Bowel Crohn’s Disease Is Superior to That of MR Enterography or CT Enterography. Clin. Gastroenterol. Hepatol. 2010;9:124–129.e1. doi: 10.1016/j.cgh.2010.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2010.10.019</ArticleId><ArticleId IdType="pubmed">21056692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruining D.H., Oliva S., Fleisher M.R., Fischer M., Fletcher J.G. Panenteric capsule endoscopy versus ileocolonoscopy plus magnetic resonance enterography in Crohn’s disease: A multicentre, prospective study. BMJ Open Gastroenterol. 2020;7:e000365. doi: 10.1136/bmjgast-2019-000365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgast-2019-000365</ArticleId><ArticleId IdType="pmc">PMC7282309</ArticleId><ArticleId IdType="pubmed">32499275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopylov U., Klang E., Yablecovitch D., Lahat A., Avidan B., Neuman S., Levhar N., Greener T., Rozendorn N., Beytelman A., et al. Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn’s disease. Ther. Adv. Gastroenterol. 2016;9:655–663. doi: 10.1177/1756283X16649143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756283X16649143</ArticleId><ArticleId IdType="pmc">PMC4984327</ArticleId><ArticleId IdType="pubmed">27582877</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel S., Bruining D.H., Loftus E.V., Becker B., Fletcher J.G., Mandrekar J.N., Zinsmeister A.R., Sandborn W.J. Endoscopic skipping of the distal terminal ileum in Crohn’s disease can lead to negative results from ileocolonoscopy. Clin. Gastroenterol. Hepatol. 2012;10:1253–1259. doi: 10.1016/j.cgh.2012.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.03.026</ArticleId><ArticleId IdType="pubmed">22503995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansuri I., Fletcher J.G., Bruining D.H., Kolbe A.B., Fidler J.L., Samuel S., Tung J. Endoscopic skipping of the terminal ileum in pediatric Crohn disease. Am. J. Roentgenol. 2017;208:W216–W224. doi: 10.2214/AJR.16.16575.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.16.16575</ArticleId><ArticleId IdType="pubmed">28379745</ArticleId></ArticleIdList></Reference><Reference><Citation>Koulaouzidis A., Douglas S., Rogers M.A., Arnott I.D., Plevris J.N. Fecal calprotectin: A selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand. J. Gastroenterol. 2011;46:561–566. doi: 10.3109/00365521.2011.551835.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.551835</ArticleId><ArticleId IdType="pubmed">21269246</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteiro S., Barbosa M., Gonçalves T.C., Carvalho P.B., Moreira M.J., Rosa B., Cotter J. Fecal Calprotectin as a Selection Tool for Small Bowel Capsule Endoscopy in Suspected Crohn’s Disease. Inflamm. Bowel Dis. 2018;24:2033–2038. doi: 10.1093/ibd/izy098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izy098</ArticleId><ArticleId IdType="pubmed">29722829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Horin S., Lahat A., Amitai M.M., Klang E., Yablecovitch D., Neuman S., Levhar N., Selinger L., Rozendorn N., Turner D., et al. Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn’s disease flare: A prospective cohort study. Lancet Gastroenterol. Hepatol. 2019;4:519–528. doi: 10.1016/S2468-1253(19)30088-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(19)30088-3</ArticleId><ArticleId IdType="pubmed">31080097</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen P.A.S., Fossmark R., Qvigstad G. Fecal calprotectin in patients with suspected small bowel disease—A selection tool for small bowel capsule endoscopy? Scand. J. Gastroenterol. 2014;50:272–277. doi: 10.3109/00365521.2014.1003395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2014.1003395</ArticleId><ArticleId IdType="pubmed">25591948</ArticleId></ArticleIdList></Reference><Reference><Citation>Menees S.B., Powell C., Kurlander J., Goel A., Chey W.D. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol. 2015;110:444–454. doi: 10.1038/ajg.2015.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2015.6</ArticleId><ArticleId IdType="pubmed">25732419</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>